Established in China for 30 years, Sanofi is a global integrated healthcare leader focused on patients’ needs and engaged in the research, development, manufacturing and marketing of innovative solutions. Our strategy is based on seven growth platforms: diabetes, vaccines, innovative solutions, consumer healthcare, emerging markets, animal health and Genzyme for rare disease and multiple sclerosis. With over 110,000 employees in 100 countries and 112 industrial sites, we act to protect health, enhance life and respond to the needs of the 7 billion people around the world. In China, we employ 7 400 people, operating in 11 regional offices and 7 manufacturing plants. Our sponsorship of this 50th anniversary of the establishment of diplomatic relationships between France and China reflects our commitment to global economic growth and public health.
This commitment started 30 years ago when Sanofi became the first foreign pharmaceutical group to open offices in China. Between 1982 and 1988, the Group has signed Traditional Chinese Medicine research agreement with Shanghai and Beijing Institute of Materia Medica, Chinese Academy of Sciences. Furthermore, in 1995, Sanofi established the first French pharmaceutical joint venture in China with the Hangzhou-based pharmaceutical company Minsheng Pharmaceutical Group which is wholly owned by Sanofi since 2009. One year later, Pasteur Merieux Connaught became the first multinational vaccine company to establish in China. Since 2005, the Group established its China Clinical Research Unit in Shanghai to conduct high quality trials and contribute to global clinical development. In 2007, Sanofi Pasteur announced investment in a world-class flu vaccine facility in Shenzhen. In 2008, Sanofi has set up a China R&D Center in Shanghai to speed up our research for the benefit of the Chinese population. Lastly, in 2011, Sanofi acquired BMP Sunstone to expand its presence in consumer healthcare in China
05 七月 2014
15 十月 2014